Humanized antibodies that recognize beta amyloid peptide
6 Assignments
0 Petitions
Accused Products
Abstract
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
-
Citations
54 Claims
- 1. Humanized 3D6 antibody.
-
2. A humanized antibody, or fragment thereof, comprising a humanized light chain comprising three light chain complementarily determining regions (CDRs) from the mouse monoclonal antibody 3D6 and a light chain variable region framework sequence from a human immunoglobulin light chain;
- and a humanized heavy chain comprising three heavy chain CDRs from the mouse monoclonal antibody 3D6 and a heavy chain variable region framework sequence from a human immunoglobulin heavy chain;
wherein the light chain CDRs have the following amino acid sequences;
- and a humanized heavy chain comprising three heavy chain CDRs from the mouse monoclonal antibody 3D6 and a heavy chain variable region framework sequence from a human immunoglobulin heavy chain;
-
5. A humanized antibody or fragment thereof comprising a humanized light chain variable region having complementarily determining regions (CDRs) from SEQ ID NO:
- 2 and variable region framework sequence from a human immunoglobulin light chain having substantial sequence identity to the sequence of SEQ ID NO;
6, and a humanized heavy chain variable region having CDRs from SEQ ID NO;
4 and variable region framework sequence from a human immunoglobulin heavy chain having substantial sequence identity to the sequence of SEQ ID NO;
9.
- 2 and variable region framework sequence from a human immunoglobulin light chain having substantial sequence identity to the sequence of SEQ ID NO;
-
6. A humanized antibody or fragment thereof comprising a humanized light chain variable region sequence substantially identical to SEQ ID NO:
- 5 and having a substitution in at least one of positions L7, L10, L12, L15, L17, L39, L45, L63, L78, L83, L85, L100 or L104, and a humanized heavy chain variable region sequence substantially identical to SEQ ID NO;
8 and having a substitution in at least one of the positions H3, H5, H13, H16, H19, H40, H41, H42, H44, H72, H77, H82H83, H84 or H108.
- 5 and having a substitution in at least one of positions L7, L10, L12, L15, L17, L39, L45, L63, L78, L83, L85, L100 or L104, and a humanized heavy chain variable region sequence substantially identical to SEQ ID NO;
-
16. A polynucleotide comprising a sequence that codes for a light chain variable region having complementarily determining regions (CDRs) from SEQ ID NO:
- 2 and variable region framework sequence from a human immunoglobulin light chain having substantial sequence identity to the sequence of SEQ ID NO;
6.
- 2 and variable region framework sequence from a human immunoglobulin light chain having substantial sequence identity to the sequence of SEQ ID NO;
-
17. A polynucleotide comprising a sequence that codes for a light chain variable region sequence substantially identical to SEQ ID NO:
- 5 and having a substitution in at least one of positions L7, L10, L12, L15, L17, L39, L45, L63, L78, L83, L85, L100 or L104.
-
18. A polynucleotide comprising a sequence that codes for a heavy chain variable region having CDRs from SEQ ID NO:
- 4 and variable region framework sequence from a human immunoglobulin heavy chain having substantial identity to the sequence of SEQ ID NO;
9.
- 4 and variable region framework sequence from a human immunoglobulin heavy chain having substantial identity to the sequence of SEQ ID NO;
-
19. A polynucleotide comprising a sequence that codes for a heavy chain variable region sequence substantially identical to SEQ ID NO:
- 8 an having a substitution in at least one of the positions H3, H5, H13, H16, H19, H40, H41, H42, H44, H72, H77, H82H83, H84 or H108.
-
33. An antibody comprising a sequence having at least 95% identity with the sequence given by SEQ ID NO:
- 71 and a sequence having at least 95% identity with the sequence given by SEQ ID NO;
72. - View Dependent Claims (34, 35, 36, 37)
- 71 and a sequence having at least 95% identity with the sequence given by SEQ ID NO;
-
38. An antibody comprising a light chain comprising a sequence having at least 95% identity with the sequence given by SEQ ID NO:
- 71 and a heavy chain comprising a sequence having at least 95% identity with the sequence given by SEQ ID NO;
72. - View Dependent Claims (39, 40, 41, 42, 43, 44, 45, 46, 47)
- 71 and a heavy chain comprising a sequence having at least 95% identity with the sequence given by SEQ ID NO;
-
48. An antibody fragment comprising a sequence having at least 95% identity with the sequence given by SEQ ID NO:
- 71 and comprising a sequence having at least 95% identity with the sequence given by SEQ ID NO;
72 - View Dependent Claims (49, 50, 51, 52, 53, 54)
- 71 and comprising a sequence having at least 95% identity with the sequence given by SEQ ID NO;
Specification